Skip to main content

Posts

Featured post

Defensive Growth in Healthcare Mega Caps

There’s a certain kind of investor who treats the stock market like a casino attached to a caffeine laboratory. Every week they’re chasing the next AI moonshot, the next quantum computing miracle, the next startup promising to “disrupt” an industry nobody asked to be disrupted in the first place. These people wake up every morning spiritually prepared to lose 18% of their net worth before breakfast. I used to envy them. Not because they were making money — most of them were just aggressively converting optimism into tax-loss harvesting opportunities — but because they seemed to possess something I lacked: faith. Faith in exponential growth. Faith in innovation. Faith that a company with no profits, no moat, and a CEO who dresses like a motivational podcaster was somehow worth 47 times future sales. Then reality happened. Inflation happened. Rate hikes happened. Market corrections happened. Geopolitical chaos happened. And suddenly investors rediscovered something Wall Street p...
Post a Comment
Read more
Recent posts

Event-Driven Biopharma Investing: How I Learned to Stop Trusting Headlines and Start Reading Trial Data

Biopharma investing is one of the only corners of the stock market where a single PDF can vaporize billions of dollars before lunch. One press release. One trial update. One sentence containing the phrase “did not meet the primary endpoint.” And suddenly a company that Wall Street analysts were calling “promising” on Tuesday becomes a financial crime scene by Wednesday morning. I love it. Not because I enjoy watching retail investors emotionally disintegrate in real time, although biotech Twitter certainly provides enough public meltdowns to qualify as performance art. I love it because event-driven biopharma investing is one of the last places in modern markets where actual research still matters. Not vibes. Not influencer charisma. Not “this stock has momentum bro.” Data matters. Cold, clinical, unforgiving data. This is an arena where billion-dollar outcomes hinge on progression-free survival curves, hazard ratios, FDA language, subgroup analyses, and whether patients re...
Post a Comment
Read more

Milestones and Multiples: Why Drug Development Investing Feels Like Gambling Inside a Chemistry Lab

There’s a very specific kind of madness that exists inside biotech investing. Not normal Wall Street madness. Not meme-stock madness. Not “a guy on YouTube said this stock could 100x” madness. No, biotech investing is different. Biotech investing is watching a company burn cash for eight straight years while investors cheer because a molecule successfully reduced inflammation in twelve mice and one extremely optimistic PowerPoint presentation. It’s an industry where billion-dollar valuations can appear overnight because a Phase 2 trial produced “encouraging signals,” which is scientific language for: “Please don’t look too closely at the sample size.” And yet I keep coming back to it. Because nothing in the market captures the intoxicating combination of hope, science, desperation, greed, and existential uncertainty quite like drug development catalysts. This is where finance becomes psychological theater. Every biotech investor eventually learns the same brutal truth: You ...
Post a Comment
Read more

Income in a Momentum Market: How to Monetize Volatility

There’s a particular kind of insanity that infects investors during a momentum market. You can feel it in the air. Suddenly everybody becomes a genius. The guy who bought three shares of an AI stock after watching two YouTube videos starts speaking with the confidence of a Roman emperor surveying conquered territory. Financial influencers begin posting rocket emojis like they personally invented capitalism. CNBC anchors start sweating with excitement every time a stock chart resembles the north face of Mount Everest. And somewhere in the middle of this collective dopamine festival sits the income investor. Confused. Slightly bitter. Holding a dividend portfolio that’s politely crawling upward at 4% while momentum traders are posting screenshots of gains large enough to purchase minor European castles. I know this feeling because I’ve lived it. Momentum markets mess with your psychology in ways people rarely admit publicly. They create emotional FOMO so intense that even discip...
Post a Comment
Read more